ANI Pharmaceuticals Inc.

57.49+0.9900+1.75%Vol 90.37K1Y Perf 71.42%
Oct 4th, 2023 16:00 DELAYED
BID56.04 ASK59.82
Open56.40 Previous Close56.50
Pre-Market- After-Market57.55
 - -  0.06 0.10%
Target Price
43.25 
Analyst Rating
Strong Buy 1.00
Potential %
-24.77 
Finscreener Ranking
★★★★     52.98
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★★+     49.02
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
+     31.62
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
75.78 
Earnings Rating
Strong Buy
Market Cap1.17B 
Earnings Date
8th Nov 2023
Alpha0.00 Standard Deviation0.13
Beta1.07 

Today's Price Range

56.2858.14

52W Range

31.2165.89

5 Year PE Ratio Range

-410.20213.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-2.38%
1 Month
-8.48%
3 Months
7.54%
6 Months
49.79%
1 Year
71.42%
3 Years
97.36%
5 Years
4.55%
10 Years
414.68%

TickerPriceChg.Chg.%
ANIP57.490.99001.75
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
2.40
3.80
0.46
0.92
-2.50
Leverage Ratio 2.40
ProfitabilityValueIndustryS&P 500US Markets
51.80
-22.20
-1.80
-8.50
-19.65
RevenueValueIndustryS&P 500US Markets
222.15M
12.73
1.77
6.72
Earnings HistoryEstimateReportedSurprise %
Q02 20230.451.06135.56
Q01 20230.160.97506.25
Q04 20220.490.5920.41
Q03 20220.400.4615.00
Q02 2022-0.04-0.05-25.00
Q01 2022-0.05-0.27-440.00
Q04 20210.690.38-44.93
Q03 20210.550.8350.91
Earnings Per EndEstimateRevision %Trend
9/2023 QR0.5510.00Positive
12/2023 QR0.686.25Positive
12/2023 FY3.1723.83Positive
12/2024 FY3.47-1.14Negative
Next Report Date8th Nov 2023
Estimated EPS Next Report0.55
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume90.37K
Shares Outstanding20.29K
Shares Float12.16M
Trades Count3.21K
Dollar Volume5.19M
Avg. Volume142.36K
Avg. Weekly Volume125.48K
Avg. Monthly Volume153.74K
Avg. Quarterly Volume147.86K

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 56.5 per share at the end of the most recent trading day (a -0.65% change compared to the prior day closing price) with a volume of 80.25K shares and market capitalization of 1.17B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.

The one-year performance of ANI Pharmaceuticals Inc. stock is 71.42%, while year-to-date (YTD) performance is 42.9%. ANIP stock has a five-year performance of 4.55%. Its 52-week range is between 31.21 and 65.89, which gives ANIP stock a 52-week price range ratio of 75.78%

ANI Pharmaceuticals Inc. currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 2.46, a price-to-sale (PS) ratio of 3.32, a price to cashflow ratio of 100.40, a PEG ratio of -, a ROA of -12.16%, a ROC of -10.06% and a ROE of -29.20%. The company’s profit margin is -19.65%, its EBITDA margin is -1.80%, and its revenue ttm is $222.15 Million , which makes it $12.73 revenue per share.

Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.55 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is 08th Nov 2023.

The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Strong Buy (1), with a target price of $43.25, which is -24.77% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ANI Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.65, ATR14 : 1.77, CCI20 : -147.48, Chaikin Money Flow : -0.31, MACD : -0.83, Money Flow Index : 16.27, ROC : -9.44, RSI : 35.55, STOCH (14,3) : 9.86, STOCH RSI : 0.00, UO : 42.22, Williams %R : -90.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Gassert Chad (Sold 20 000 shares of value $1 026 400 ), Shanmugam Muthusamy (Sold 23 469 shares of value $1 220 844 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (60.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (20.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Moderate Buy
1.60

ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.

CEO: Nikhil Lalwani

Telephone: +1 218 634-3500

Address: 210 Main Street West, Baudette 56623, MN, US

Number of employees: 338

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

60%40%

Bearish Bullish

61%39%

 

News

Stocktwits